Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA

Watchlist Manager
Sun Pharmaceutical Industries Ltd Logo
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Watchlist
Price: 1 787.4 INR -0.91% Market Closed
Market Cap: 4.3T INR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
-7%
Revenue
Forecast
-11%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

SUNPHARMA Price Targets Summary
Sun Pharmaceutical Industries Ltd

Wall Street analysts forecast SUNPHARMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SUNPHARMA is 2 057.31 INR with a low forecast of 1 515 INR and a high forecast of 2 572.5 INR.

SUNPHARMA Lowest Forecast
Wall Street Target
1 515 INR
15% Downside
SUNPHARMA Average Forecast
Wall Street Target
2 057.31 INR
15% Upside
SUNPHARMA Highest Forecast
Wall Street Target
2 572.5 INR
44% Upside
Lowest
Price Target
1 515 INR
15% Downside
Average
Price Target
2 057.31 INR
15% Upside
Highest
Price Target
2 572.5 INR
44% Upside
Sun Pharmaceutical Industries Ltd Competitors:
Price Targets
PFIZER
Pfizer Ltd
43% Upside
ANCR
Animalcare Group PLC
39% Upside
M
4016
Middle East Pharmaceutical Industries Company SJSC
10% Upside
D
DHG
Dhg Pharmaceutical Joint-Stock Co
12% Upside
PFIZER
Pfizer Ltd
43% Upside
ANCR
Animalcare Group PLC
39% Upside
M
4016
Middle East Pharmaceutical Industries Company SJSC
10% Upside
D
DHG
Dhg Pharmaceutical Joint-Stock Co
12% Upside
4540
Tsumura & Co
30% Upside
AUROPHARMA
Aurobindo Pharma Ltd
23% Upside
N
603707
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
75% Upside
6622
Zhaoke Ophthalmology Ltd
47% Upside

Revenue
Forecast

Revenue Estimate
Sun Pharmaceutical Industries Ltd

For the last 8 years the compound annual growth rate for Sun Pharmaceutical Industries Ltd's revenue is 7%. The projected CAGR for the next 4 years is 10%.

7%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Sun Pharmaceutical Industries Ltd

For the last 8 years the compound annual growth rate for Sun Pharmaceutical Industries Ltd's operating income is 4%. The projected CAGR for the next 4 years is 17%.

4%
Past Growth
17%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Sun Pharmaceutical Industries Ltd

For the last 8 years the compound annual growth rate for Sun Pharmaceutical Industries Ltd's net income is 10%. The projected CAGR for the next 4 years is 17%.

10%
Past Growth
17%
Estimated Growth
Estimates Accuracy
-15%
Average Miss
What are analyst estimates?

See Also

Summary
SUNPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
SUNPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SUNPHARMA stock valuation using valuation multiples.
Wall Street Estimates
SUNPHARMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SUNPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SUNPHARMA's stock price target?
Price Target
2 057.31 INR

According to Wall Street analysts, the average 1-year price target for SUNPHARMA is 2 057.31 INR with a low forecast of 1 515 INR and a high forecast of 2 572.5 INR.

What is Sun Pharmaceutical Industries Ltd's Revenue forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for Sun Pharmaceutical Industries Ltd's revenue is 7%. The projected CAGR for the next 4 years is 10%.

What is Sun Pharmaceutical Industries Ltd's Operating Income forecast?
Projected CAGR
17%

For the last 8 years the compound annual growth rate for Sun Pharmaceutical Industries Ltd's operating income is 4%. The projected CAGR for the next 4 years is 17%.

What is Sun Pharmaceutical Industries Ltd's Net Income forecast?
Projected CAGR
17%

For the last 8 years the compound annual growth rate for Sun Pharmaceutical Industries Ltd's net income is 10%. The projected CAGR for the next 4 years is 17%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 250,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.